Stock Groups

CDC taps Palantir to support COVID-19 drug supply in U.S -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: This is the logo of Palantir Technologies (USA) seen in Davos Switzerland, January 22nd 2020. REUTERS/Arnd Wiegmann/File Photo/File Photo/File Photo

(Reuters) – Palantir Technologies (NYSE) Inc has been awarded a $5.3million contract by the Centers for Disease Control and Prevention to oversee distribution of COVID-19 medicines in the United States. The software maker announced Tuesday.

Palantir stated that the contract to support distribution of therapeutics lasts for six months.

Palantir’s Tiberius platform is already being used for vaccine distribution. This partnership was established in 2020.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, futures, indexes or Forex. The prices of Forex and CFDs are provided by market makers and are therefore not necessarily accurate. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of the potential risks and financial costs involved in trading the financial market. It is among the most dangerous investment options.

[ad_2]